It is reported that immunotyping can indicate tumor immune microenvironment, thus predicting responses to immunotherapy.10 Accordingly, the construction of cancer immune subtypes might be favorable to selecting suitable patients for TGFB inhibition. This evidence concerns the gene TGFB1 and neoplasm.